Communication Strategies for Mechanically Ventilated Patients in Intensive Care Units

December 13, 2022 updated by: Emilie Szymkowicz, University of Liege

Comparative Analysis of Communication Board and Eye Tracking in Intensive Care Mechanically Ventilated Patients

This prospective study consisted of (1) a descriptive cross-sectional part describing communication difficulties related to mechanical ventilation as experienced by intensive care professionals and patients, and (2) an experimental randomized crossover part comparing the use of a conventional low-tech communication board and a high-tech eye tracking technology-based device to improve communication effectiveness of intensive care mechanically ventilated patients.

Study Overview

Detailed Description

Sample size:

The health professionals sample size is estimated by convenience to 100 professionals based on the accessible population in the study site (i.e., 95% of the health professionals from the study site). The patients sample size is estimated to 44 patients based on statistical calculation (with a type 1 error rate of 5%, a type 2 error rate of 10% and an allocation ratio of 1), including two groups of 22 patients.

Intervention:

The cross-sectional part involved the healthcare professionals through the "state of the art questionnaire" and the patients through the "ease of communication scale". The crossover part then randomized the patients from the cross-sectional part into two groups and the communication interfaces were divided into two time periods: group A received eye tracking/communication board sequence and group B received communication board/eye tracking sequence. For each period, the communication interfaces were evaluated through the "intervention form". The communication board provides simple messages based on orthographic and iconic content. The eye tracking computer-based system enables the production and construction of simple or complex messages (including word processing with spelling suggestions and voice synthesis), also based on orthographic and iconic content.

Statistical analysis:

The numerical data will be analyzed quantitatively using R software (version 2016 3.5.3). The Gaussian distribution will be estimated by mean/median comparison, histogram symmetry, quantile-quantile distribution and shapiro-wilk test. Statistical analysis of the crossover variables (treatment-period interaction, period effect, and treatment effect) will be performed using the Mann-Whitney (ordinal variables) and chi-square (binary variables) nonparametric tests. A p-value less than 0.05 was considered significant. The non-numerical data will be analyzed qualitatively by thematization and categorization.

Ethics approval and consent to participate:

The study protocol was approved by the Ethics Committee of the Hospital of Liège as Central Committee and the Hospital of Charleroi as Local Committee (number: B70720183767, reference: 2018/268). The information and consent documents intended for healthcare professionals and patients were validated by both Ethics Committees. Written informed consent was obtained from all participants (healthcare professionals and patient's legal representative) included in this study. All procedures performed through this study were in accordance with the 1964 Helsinki Declaration and its later amendments.

Study Type

Interventional

Enrollment (Actual)

44

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Liège, Belgium, 4000
        • University of Liege

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria - healthcare professionals:

  • Working in the intensive care unit (study site).

Exclusion Criteria - healthcare professionals:

  • Lack of consent.

Inclusion Criteria - patients:

  • Being hospitalized in the intensive care unit (study site),
  • Awake with a Richmond Agitation-Sedation Scale (RASS) between "restless" (+1) and "drowsy" (-1),
  • Age of 18 years or older,
  • French speaker.

Exclusion Criteria - patients:

  • Lack of consent,
  • Severe visual impairment (e.g., blindness).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Communication board
The communication board consists of a printed paper interface with a size of 42 x 30 cm.
The comparison between the communication board and eye tracking, conducted as a crossover, generates a randomization of the patients (from the cross-sectional part) into two groups and the communication interfaces were divided into two time periods: group A received eye tracking/communication board sequence and group B received communication board/eye tracking sequence.
Experimental: Eye tracking
The eye tracking device combines a laptop computer with a screen size of 29 x 16 cm, an eye tracker (PCEye Mini, Tobii dynavox, Danderyd, Sweden), an interface generated by a communication software (Communicator 5, Tobii dynavox) and a telescopic support.
The comparison between the communication board and eye tracking, conducted as a crossover, generates a randomization of the patients (from the cross-sectional part) into two groups and the communication interfaces were divided into two time periods: group A received eye tracking/communication board sequence and group B received communication board/eye tracking sequence.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
State of the art questionnaire - communication difficulties related to mechanical ventilation as experienced by healthcare professionals.
Time Frame: Before the use of communication interfaces.
Self-administered questionnaire assessing the difficulties to communicate with intubated or tracheostomized patients, the avoidance of interactions with patients, the perception of the help that could be provided by alternative communication systems and the interest in learning to use these systems.
Before the use of communication interfaces.
Ease of communication scale (ECS) - communication difficulties related to mechanical ventilation as experienced by patients.
Time Frame: Before the use of communication interfaces.
Multidimensional scale completed through an assisted interview and covering the difficulty to be understood; to communicate physical needs, thoughts, and feelings with notably relatives, nurses and physicians; and to ask questions about care and health status.
Before the use of communication interfaces.
Quantity of messages transmitted through the communication board.
Time Frame: During the use of communication interfaces.
Communication effectiveness indicator, collected through the intervention form.
During the use of communication interfaces.
Quantity of messages transmitted through the eye tracking.
Time Frame: During the use of communication interfaces.
Communication effectiveness indicator, collected through the intervention form.
During the use of communication interfaces.
Success rate for the communication board.
Time Frame: During the use of communication interfaces.
Communication effectiveness indicator, collected through the intervention form.
During the use of communication interfaces.
Success rate for the eye tracking.
Time Frame: During the use of communication interfaces.
Communication effectiveness indicator, collected through the intervention form.
During the use of communication interfaces.
Level of satisfaction for the communication board.
Time Frame: During the use of communication interfaces.
Communication effectiveness indicator, collected through the intervention form.
During the use of communication interfaces.
Level of satisfaction for the eye tracking.
Time Frame: During the use of communication interfaces.
Communication effectiveness indicator, collected through the intervention form.
During the use of communication interfaces.
Communication content for the communication board.
Time Frame: During the use of communication interfaces.
Communication effectiveness indicator, collected through the intervention form.
During the use of communication interfaces.
Communication content for the eye tracking.
Time Frame: During the use of communication interfaces.
Communication effectiveness indicator, collected through the intervention form.
During the use of communication interfaces.
Difficulties of use related to the communcation board.
Time Frame: During the use of communication interfaces.
Communication effectiveness indicator, collected through the intervention form.
During the use of communication interfaces.
Difficulties of use related to the eye tracking.
Time Frame: During the use of communication interfaces.
Communication effectiveness indicator, collected through the intervention form.
During the use of communication interfaces.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Stephan Ehrmann, MD, PhD, University hospital and University of Tours
  • Study Director: Laetitia Bodet-Contentin, MD, PhD, University hospital and University of Tours
  • Principal Investigator: Yoann Marechal, MD, PhD, University hospital of Charleroi
  • Principal Investigator: Emilie Szymkowicz, MSc, University of Liege

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 9, 2019

Primary Completion (Actual)

June 27, 2019

Study Completion (Actual)

June 27, 2019

Study Registration Dates

First Submitted

December 2, 2022

First Submitted That Met QC Criteria

December 13, 2022

First Posted (Estimate)

December 15, 2022

Study Record Updates

Last Update Posted (Estimate)

December 15, 2022

Last Update Submitted That Met QC Criteria

December 13, 2022

Last Verified

December 1, 2022

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe